JP2010524489A5 - - Google Patents

Download PDF

Info

Publication number
JP2010524489A5
JP2010524489A5 JP2010504835A JP2010504835A JP2010524489A5 JP 2010524489 A5 JP2010524489 A5 JP 2010524489A5 JP 2010504835 A JP2010504835 A JP 2010504835A JP 2010504835 A JP2010504835 A JP 2010504835A JP 2010524489 A5 JP2010524489 A5 JP 2010524489A5
Authority
JP
Japan
Prior art keywords
binding domain
amino acid
acid sequence
sequence shown
domain consisting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010504835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010524489A (ja
Filing date
Publication date
Priority claimed from GBGB0708002.1A external-priority patent/GB0708002D0/en
Application filed filed Critical
Publication of JP2010524489A publication Critical patent/JP2010524489A/ja
Publication of JP2010524489A5 publication Critical patent/JP2010524489A5/ja
Pending legal-status Critical Current

Links

JP2010504835A 2007-04-25 2008-04-23 Ｒａｍｐ３に対する抗体 Pending JP2010524489A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0708002.1A GB0708002D0 (en) 2007-04-25 2007-04-25 Antibodies
PCT/GB2008/001454 WO2008132453A1 (en) 2007-04-25 2008-04-23 Antibodies against ramp3

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014102881A Division JP6086495B2 (ja) 2007-04-25 2014-05-16 Ｒａｍｐ３に対する抗体

Publications (2)

Publication Number Publication Date
JP2010524489A JP2010524489A (ja) 2010-07-22
JP2010524489A5 true JP2010524489A5 (Direct) 2011-06-16

Family

ID=38170659

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010504835A Pending JP2010524489A (ja) 2007-04-25 2008-04-23 Ｒａｍｐ３に対する抗体
JP2014102881A Expired - Fee Related JP6086495B2 (ja) 2007-04-25 2014-05-16 Ｒａｍｐ３に対する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014102881A Expired - Fee Related JP6086495B2 (ja) 2007-04-25 2014-05-16 Ｒａｍｐ３に対する抗体

Country Status (10)

Country Link
US (2) US8389237B2 (Direct)
EP (1) EP2152753B1 (Direct)
JP (2) JP2010524489A (Direct)
KR (1) KR20100015915A (Direct)
CN (1) CN101842390A (Direct)
AU (1) AU2008244074B2 (Direct)
CA (1) CA2685099A1 (Direct)
ES (1) ES2393938T3 (Direct)
GB (1) GB0708002D0 (Direct)
WO (1) WO2008132453A1 (Direct)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
GB0521139D0 (en) * 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
RU2511406C2 (ru) 2006-06-08 2014-04-10 Чугаи Сейяку Кабусики Кайся Профилактическое или лекарственное средство для воспалительного заболевания
EP2543389A3 (en) 2007-08-02 2013-04-24 Gilead Biologics, Inc. Methods and compositions inhibiting a lysyl oxidase (-like) protein for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
KR102467302B1 (ko) 2007-09-26 2022-11-14 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
BRPI0821145B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo anti-nr10 como agente preventivo ou terapêutico para prurido
KR101840994B1 (ko) 2007-12-05 2018-03-21 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
AU2009241589B2 (en) * 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9109026B2 (en) * 2008-06-03 2015-08-18 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
TW201012475A (en) * 2008-07-08 2010-04-01 Abbott Lab Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
KR20160062207A (ko) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP3674317B1 (en) 2009-03-19 2024-12-11 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
MX2011011670A (es) * 2009-05-01 2011-11-18 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las mismas.
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
RU2012110585A (ru) 2009-08-21 2013-09-27 Джилид Байолоджикс, Инк. Каталичические домены лизилоксидазы и loxl2
BR112012008833A2 (pt) * 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
NZ607480A (en) 2010-08-03 2014-10-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
PH12013500337A1 (en) 2010-08-26 2017-08-23 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
TWI761912B (zh) 2010-11-30 2022-04-21 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
JP6316195B2 (ja) * 2011-10-26 2018-04-25 エランコ ティーアゲズンタイト アーゲー モノクローナル抗体および使用の方法
CA2861610A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
TW201811825A (zh) 2012-11-01 2018-04-01 美商艾伯維有限公司 抗-ｖｅｇｆ／ｄｌｌ４雙重可變區域免疫球蛋白及其用途
CA2904448A1 (en) 2013-03-15 2014-09-18 Tariq Ghayur Dual specific binding proteins directed against il-1.beta. and/or il-17
US10379127B2 (en) 2013-11-27 2019-08-13 Welcome Receptor Antibodies Pty Ltd Marker of cell death
CA2960756C (en) 2014-09-15 2023-08-01 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
MA43918A (fr) 2015-04-14 2018-12-05 Chugai Pharmaceutical Co Ltd Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
EP4650370A2 (en) 2015-04-14 2025-11-19 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
GB201509907D0 (en) * 2015-06-08 2015-07-22 Urosens Ltd Antibodies
CN107771285A (zh) 2015-06-08 2018-03-06 阿奎尔诊断有限公司 方法
EP4060344A1 (en) 2015-06-08 2022-09-21 Arquer Diagnostics Limited Methods and kits
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
AU2017254674A1 (en) * 2016-04-21 2018-11-01 Abbvie Stemcentrx Llc Novel anti-BMPR1B antibodies and methods of use
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
WO2019195185A1 (en) 2018-04-02 2019-10-10 Amgen Inc. Erenumab compositions and uses thereof
US12156918B2 (en) 2018-10-08 2024-12-03 The Uab Research Foundation Neuroendocrine cancer targeted therapy
GB201818651D0 (en) 2018-11-15 2019-01-02 Univ Sheffield Compounds
GB201818649D0 (en) 2018-11-15 2019-01-02 Univ Sheffield Compounds
TWI860426B (zh) 2019-11-20 2024-11-01 日商中外製藥股份有限公司 含有抗體之製劑
CN113512109B (zh) * 2021-03-09 2022-03-25 北京康乐卫士生物技术股份有限公司 一种抗人乳头瘤病毒31型的单克隆中和抗体及其应用
WO2024102912A1 (en) * 2022-11-10 2024-05-16 The Children's Medical Center Corporation Cgrp/ramp1 blockade to treat endometriosis-associated pain and reduce endometriosis lesions
GB202303531D0 (en) * 2023-03-10 2023-04-26 Fusion Antibodies Plc Antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055231A1 (en) * 1998-10-28 2003-03-20 Jian Ni 12 human secreted proteins
AU2003298708A1 (en) 2002-11-27 2004-06-23 Genpath Pharmaceuticals, Incorporated GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent

Similar Documents

Publication Publication Date Title
JP2010524489A5 (Direct)
JP2012121878A5 (Direct)
JP2012522010A5 (Direct)
JP2019522490A5 (Direct)
JP2019510739A5 (Direct)
JP2010511388A5 (Direct)
JP2006506333A5 (Direct)
JP2014509187A5 (Direct)
JP2013519364A5 (Direct)
JP2020517635A5 (Direct)
CA2624935A1 (en) Anti-myostatin antibodies
JP2009511579A5 (Direct)
JP2009511480A5 (Direct)
EA200801520A1 (ru) Химерные и гуманизированные антитела против человеческого интерлейкина-13 (il-13)
JP2012525128A5 (Direct)
JP2015525791A5 (Direct)
JP2009515831A5 (Direct)
JP2008516970A5 (Direct)
JP2010533498A5 (Direct)
JP2012010714A5 (Direct)
JP2011502137A5 (Direct)
JP2010531140A5 (Direct)
JP2011157378A5 (Direct)
WO2008036341A3 (en) Compositions and methods relating to glucagon receptor antibodies
JP2008525033A5 (Direct)